Arca
Skip to content
Tools
Tools

TIGIT: T-cell immunoreceptor with Ig and ITIM domains

Inhibitory receptor that plays a role in the modulation of immune responses.

  • Drugs that act on it: 7
  • Approved: 0
  • In phases 1 to 3: 7
  • Sponsors: 7

Who is on it, and how far along

Every drug ChEMBL records acting on TIGIT, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 5
  • Other 2

Approved0

    Phase 34

    • Tiragolumab
    • Domvanalimab
    • Vibostolimab
    • Ociperlimab

    Phase 21

    • Etigilimab

    Phase 12

    • ASP-8374
    • IBI-939

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Innovent Biologics (Suzhou) Co. Ltd.114%
    • Mereo BioPharma114%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 5 of 7 act as: T-cell immunoreceptor with Ig and ITIM domains inhibitor; the rest name their own mechanism.
    TiragolumabPhase 3RocheAntibodyInhibitor23
    DomvanalimabPhase 3Gilead SciencesAntibodyInhibitor13
    VibostolimabPhase 3Merck & Co. (MSD)AntibodyAntagonistT-cell immunoreceptor with Ig and ITIM domains antagonist5
    OciperlimabPhase 3BeOne MedicinesAntibodyInhibitor0
    EtigilimabPhase 2Mereo BioPharmaAntibodyInhibitor1
    ASP-8374Phase 1Astellas PharmaOtherAntagonistT-cell immunoreceptor with Ig and ITIM domains antagonist0
    IBI-939Phase 1Innovent Biologics (Suzhou) Co. Ltd.OtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov.
    Radiotherapy Plus Putelimab and Vibostolimab for Advanced Anal Squamous Cell CarcinomaVibostolimabPhase 2Not yet recruitingFudan UniversityNov 13, 2026
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal HypertensionTiragolumabPhase 2Not yet recruitingTongji HospitalJan 20, 2026
    Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)DomvanalimabPhase 2Not yet recruitingHospices Civils de LyonJan 13, 2026
    IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersDomvanalimabPhase 2Active, not recruitingHospices Civils de LyonJan 24, 2025
    Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)TiragolumabPhase 1Active, not recruitingM.D. Anderson Cancer CenterJan 6, 2025
    A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryTiragolumabPhase 2Active, not recruitingM.D. Anderson Cancer CenterDec 31, 2024
    Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01DomvanalimabPhase 2Active, not recruitingGilead SciencesDec 11, 2024
    NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialTiragolumabPhase 2RecruitingThe Netherlands Cancer InstituteApr 2, 2024
    Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast CancerTiragolumabPhase 2Active, not recruitingInstitut CurieDec 18, 2023
    PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder CancerDomvanalimabPhase 2Active, not recruitingFundación para el Progreso de la Oncología en CantabriaNov 15, 2023
    Tiragolumab and Atezolizumab in Advanced Pan-cancer PatientsTiragolumabPhase 2Active, not recruitingOmicoAug 22, 2023
    A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)TiragolumabPhase 3Active, not recruitingHoffmann-La RocheJun 15, 2023
    A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyTiragolumabPhase 3RecruitingHoffmann-La RocheMay 17, 2023
    A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)VibostolimabPhase 1 / Phase 2Active, not recruitingMerck Sharp & Dohme LLCMay 6, 2023
    Domvanalimab and Zimberelimab in Advanced Liver CancersDomvanalimabPhase 2Active, not recruitingUniversity of Texas Southwestern Medical CenterFeb 13, 2023
    EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian CancerEtigilimabPhase 2Active, not recruitingM.D. Anderson Cancer CenterFeb 6, 2023
    Study With Various Immunotherapy Treatments in Participants With Lung CancerDomvanalimabPhase 2Active, not recruitingGilead SciencesJan 9, 2023
    Study of Novel Treatment Combinations in Patients With Lung CancerDomvanalimabPhase 2Active, not recruitingGilead SciencesDec 1, 2022
    Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerDomvanalimabPhase 3Active, not recruitingGilead SciencesAug 16, 2022
    Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)VibostolimabPhase 3Active, not recruitingMerck Sharp & Dohme LLCFeb 4, 2022
    KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)VibostolimabPhase 1 / Phase 2RecruitingMerck Sharp & Dohme LLCNov 15, 2019
    Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)VibostolimabPhase 1 / Phase 2Active, not recruitingMerck Sharp & Dohme LLCAug 10, 2016

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Non-small cell lung carcinoma0.42
    • Small cell lung carcinoma0.38
    • Esophageal squamous cell carcinoma0.35
    • Neurodegenerative disease0.33
    • Cancer0.31
    • Gastric adenocarcinoma0.29
    • Gastroesophageal junction adenocarcinoma0.29
    • Esophageal adenocarcinoma0.28
    • Obesity disorder0.24

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630878, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q495A1, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.